{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T21:58:05Z","timestamp":1792619885678,"version":"4.5.0"},"reference-count":133,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,4,28]],"date-time":"2024-04-28T00:00:00Z","timestamp":1714262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Antisense oligonucleotides (ASOs) are short oligodeoxynucleotides designed to bind to specific regions of target mRNA. ASOs can modulate pre-mRNA splicing, increase levels of functional proteins, and decrease levels of toxic proteins. ASOs are being developed for the treatment of motor neuron diseases (MNDs), including spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS) and spinal and bulbar muscular atrophy (SBMA). The biggest success has been the ASO known as nusinersen, the first effective therapy for SMA, able to improve symptoms and slow disease progression. Another success is tofersen, an ASO designed to treat ALS patients with SOD1 gene mutations. Both ASOs have been approved by the FDA and EMA. On the other hand, ASO treatment in ALS patients with the C9orf72 gene mutation did not show any improvement in disease progression. The aim of this review is to provide an up-to-date overview of ASO research in MNDs, from preclinical studies to clinical trials and, where available, regulatory approval. We highlight the successes and failures, underline the strengths and limitations of the current ASO research, and suggest possible approaches that could lead to more effective treatments.<\/jats:p>","DOI":"10.3390\/ijms25094809","type":"journal-article","created":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T08:02:22Z","timestamp":1714723342000},"page":"4809","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Antisense Oligonucleotides (ASOs) in Motor Neuron Diseases: A Road to Cure in Light and Shade"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5741-295X","authenticated-orcid":false,"given":"Silvia","family":"Cantara","sequence":"first","affiliation":[{"name":"Department of Medical, Surgical and Neurological Sciences, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Simoncelli","sequence":"additional","affiliation":[{"name":"Unit of Neurology and Clinical Neurophysiology, Department of Neurological and Motor Sciences, Azienda Ospedaliero-Universitaria Senese, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2431-0308","authenticated-orcid":false,"given":"Claudia","family":"Ricci","sequence":"additional","affiliation":[{"name":"Department of Medical, Surgical and Neurological Sciences, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1080\/17425255.2021.1992382","article-title":"Antisense Oligonucleotides: Absorption, Distribution, Metabolism, and Excretion","volume":"17","author":"Shadid","year":"2021","journal-title":"Expert. Opin. Drug Metab. Toxicol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev-med-041217-010829","article-title":"Therapeutic Antisense Oligonucleotides Are Coming of Age","volume":"70","author":"Bennett","year":"2019","journal-title":"Annu. Rev. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nbt.3779","article-title":"Cellular Uptake and Trafficking of Antisense Oligonucleotides","volume":"35","author":"Crooke","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5465","DOI":"10.1093\/nar\/gkz247","article-title":"Site-Specific Replacement of Phosphorothioate with Alkyl Phosphonate Linkages Enhances the Therapeutic Profile of Gapmer ASOs by Modulating Interactions with Cellular Proteins","volume":"47","author":"Migawa","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/nar\/gkad067","article-title":"Chemistry, Structure and Function of Approved Oligonucleotide Therapeutics","volume":"51","author":"Egli","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1440-1681.2006.04403.x","article-title":"Antisense Oligonucleotides: From Design to Therapeutic Application","volume":"33","author":"Chan","year":"2006","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"8796","DOI":"10.1093\/nar\/gku531","article-title":"Targeted Delivery of Antisense Oligonucleotides to Hepatocytes Using Triantennary N-Acetyl Galactosamine Improves Potency 10-Fold in Mice","volume":"42","author":"Prakash","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1093\/nar\/gkw144","article-title":"Hsp90 Protein Interacts with Phosphorothioate Oligonucleotides Containing Hydrophobic 2\u2032-Modifications and Enhances Antisense Activity","volume":"44","author":"Liang","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1089\/nat.2022.0004","article-title":"Delivery of RNA Therapeutics: The Great Endosomal Escape!","volume":"32","author":"Dowdy","year":"2022","journal-title":"Nucleic Acid Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"5692","DOI":"10.1039\/C7SC01336A","article-title":"RNA Splicing Process Analysis for Identifying Antisense Oligonucleotide Inhibitors with Padlock Probe-Based Isothermal Amplification","volume":"8","author":"Ren","year":"2017","journal-title":"Chem. Sci."},{"key":"ref_11","first-page":"489","article-title":"Phosphorothioate Oligodeoxynucleotides Distribute Similarly in Class A Scavenger Receptor Knockout and Wild-Type Mice","volume":"292","author":"Butler","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","article-title":"Treatment of Infantile-Onset Spinal Muscular Atrophy with Nusinersen: A Phase 2, Open-Label, Dose-Escalation Study","volume":"388","author":"Finkel","year":"2016","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","article-title":"Sustained Therapeutic Reversal of Huntington\u2019s Disease by Transient Repression of Huntingtin Synthesis","volume":"74","author":"Kordasiewicz","year":"2012","journal-title":"Neuron"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"72ra18","DOI":"10.1126\/scitranslmed.3001777","article-title":"Antisense Oligonucleotides Delivered to the Mouse CNS Ameliorate Symptoms of Severe Spinal Muscular Atrophy","volume":"3","author":"Passini","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1124\/jpet.113.212407","article-title":"Pharmacology of a Central Nervous System Delivered 2\u2032- O -Methoxyethyl\u2013Modified Survival of Motor Neuron Splicing Oligonucleotide in Mice and Nonhuman Primates","volume":"350","author":"Rigo","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1172\/JCI25424","article-title":"Antisense Oligonucleotide Therapy for Neurodegenerative Disease","volume":"116","author":"Smith","year":"2006","journal-title":"J. Clin. Investig."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1101\/gad.1941310","article-title":"Antisense Correction of SMN2 Splicing in the CNS Rescues Necrosis in a Type III SMA Mouse Model","volume":"24","author":"Hua","year":"2010","journal-title":"Genes. Dev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"eaag0481","DOI":"10.1126\/scitranslmed.aag0481","article-title":"Tau Reduction Prevents Neuronal Loss and Reverses Pathological Tau Deposition and Seeding in Mice with Tauopathy","volume":"9","author":"DeVos","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1172\/JCI99081","article-title":"Antisense Oligonucleotides Extend Survival and Reverse Decrement in Muscle Response in ALS Models","volume":"128","author":"McCampbell","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1146\/annurev-neuro-070918-050501","article-title":"Antisense Oligonucleotide Therapies for Neurodegenerative Diseases","volume":"42","author":"Bennett","year":"2019","journal-title":"Annu. Rev. Neurosci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.exger.2010.08.026","article-title":"Intranasal Insulin as a Therapeutic Option in the Treatment of Cognitive Impairments","volume":"46","author":"Benedict","year":"2011","journal-title":"Exp. Gerontol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"717192","DOI":"10.3389\/fphar.2021.717192","article-title":"Current State and Future Directions of Intranasal Delivery Route for Central Nervous System Disorders: A Scientometric and Visualization Analysis","volume":"12","author":"Wu","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13287-021-02274-0","article-title":"Advances in Intranasal Application of Stem Cells in the Treatment of Central Nervous System Diseases","volume":"12","author":"Zhang","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1002\/jps.21924","article-title":"Intranasal Delivery to the Central Nervous System: Mechanisms and Experimental Considerations","volume":"99","author":"Dhuria","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"8173","DOI":"10.1002\/anie.201914751","article-title":"Systemic Brain Delivery of Antisense Oligonucleotides across the Blood\u2013Brain Barrier with a Glucose-Coated Polymeric Nanocarrier","volume":"59","author":"Min","year":"2020","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41572-022-00380-8","article-title":"Spinal Muscular Atrophy","volume":"8","author":"Mercuri","year":"2022","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/ejhg.2011.134","article-title":"Pan-Ethnic Carrier Screening and Prenatal Diagnosis for Spinal Muscular Atrophy: Clinical Laboratory Analysis of >72,400 Specimens","volume":"20","author":"Sugarman","year":"2012","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/ajmg.10425","article-title":"Genetic Risk Assessment in Carrier Testing for Spinal Muscular Atrophy","volume":"110","author":"Ogino","year":"2002","journal-title":"Am. J. Med. Genet."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0960-8966(91)90039-U","article-title":"Population Frequencies of Inherited Neuromuscular Diseases\u2014A World Survey","volume":"1","author":"Emery","year":"1991","journal-title":"Neuromuscul. Disord."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"9920","DOI":"10.1073\/pnas.94.18.9920","article-title":"Inactivation of the Survival Motor Neuron Gene, a Candidate Gene for Human Spinal Muscular Atrophy, Leads to Massive Cell Death in Early Mouse Embryos","volume":"94","author":"Schrank","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Crisafulli, S., Boccanegra, B., Vitturi, G., Trifir\u00f2, G., and De Luca, A. (2023). Pharmacological Therapies of Spinal Muscular Atrophy: A Narrative Review of Preclinical, Clinical\u2013Experimental, and Real-World Evidence. Brain Sci., 13.","DOI":"10.3390\/brainsci13101446"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s004390100473","article-title":"SMN Gene Duplication and the Emergence of the SMN2 Gene Occurred in Distinct Hominids: SMN2 Is Unique to Homo Sapiens","volume":"108","author":"Rochette","year":"2001","journal-title":"Hum. Genet."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/ng854","article-title":"Disruption of an SF2\/ASF-Dependent Exonic Splicing Enhancer in SMN2 Causes Spinal Muscular Atrophy in the Absence of SMN1","volume":"30","author":"Cartegni","year":"2002","journal-title":"Nat. Genet."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1086\/498853","article-title":"Determinants of Exon 7 Splicing in the Spinal Muscular Atrophy Genes, SMN1 and SMN2","volume":"78","author":"Cartegni","year":"2006","journal-title":"Am. J. Hum. Genet."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/ng1207","article-title":"A Negative Element in SMN2 Exon 7 Inhibits Splicing in Spinal Muscular Atrophy","volume":"34","author":"Kashima","year":"2003","journal-title":"Nat. Genet."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1093\/hmg\/ddm276","article-title":"hnRNP A1 Functions with Specificity in Repression of SMN2 Exon 7 Splicing","volume":"16","author":"Kashima","year":"2007","journal-title":"Hum. Mol. Genet."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1073\/pnas.96.11.6307","article-title":"A Single Nucleotide in the SMN Gene Regulates Splicing and Is Responsible for Spinal Muscular Atrophy","volume":"96","author":"Lorson","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ajhg.2009.08.002","article-title":"A Positive Modifier of Spinal Muscular Atrophy in the SMN2 Gene","volume":"85","author":"Prior","year":"2009","journal-title":"Am. J. Hum. Genet."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1399-0004.2009.01200.x","article-title":"Genotype-Phenotype Studies in Infantile Spinal Muscular Atrophy (SMA) Type I in Germany: Implications for Clinical Trials and Genetic Counselling","volume":"76","author":"Berg","year":"2009","journal-title":"Clin. Genet."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1086\/302369","article-title":"Quantitative Analysis of Survival Motor Neuron Copies: Identification of Subtle SMN1 Mutations in Patients with Spinal Muscular Atrophy, Genotype-Phenotype Correlation, and Implications for Genetic Counseling","volume":"64","author":"Wirth","year":"1999","journal-title":"Am. J. Hum. Genet."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s00439-006-0156-7","article-title":"Mildly Affected Patients with Spinal Muscular Atrophy Are Partially Protected by an Increased SMN2 Copy Number","volume":"119","author":"Wirth","year":"2006","journal-title":"Hum. Genet."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4114","DOI":"10.1073\/pnas.0633863100","article-title":"Bifunctional Antisense Oligonucleotides Provide a Trans-Acting Splicing Enhancer That Stimulates SMN2 Gene Expression in Patient Fibroblasts","volume":"100","author":"Skordis","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e174","DOI":"10.1038\/mtna.2014.23","article-title":"A Short Antisense Oligonucleotide Ameliorates Symptoms of Severe Mouse Models of Spinal Muscular Atrophy","volume":"3","author":"Keil","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"11746","DOI":"10.1038\/srep11746","article-title":"Spinal Muscular Atrophy Phenotype Is Ameliorated in Human Motor Neurons by SMN Increase via Different Novel RNA Therapeutic Approaches","volume":"5","author":"Nizzardo","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.ajhg.2008.01.014","article-title":"Antisense Masking of an hnRNP A1\/A2 Intronic Splicing Silencer Corrects SMN2 Splicing in Transgenic Mice","volume":"82","author":"Hua","year":"2008","journal-title":"Am. J. Hum. Genet."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1128\/MCB.26.4.1333-1346.2006","article-title":"Splicing of a Critical Exon of Human Survival Motor Neuron Is Regulated by a Unique Silencer Element Located in the Last Intron","volume":"26","author":"Singh","year":"2006","journal-title":"Mol. Cell Biol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","article-title":"Results from a Phase 1 Study of Nusinersen (ISIS-SMN(Rx)) in Children with Spinal Muscular Atrophy","volume":"86","author":"Chiriboga","year":"2016","journal-title":"Neurology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/gt.2017.64","article-title":"Development of Gene Therapies\u2014Lessons from Nusinersen","volume":"24","author":"Xu","year":"2017","journal-title":"Gene Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nature10485","article-title":"Peripheral SMN Restoration Is Essential for Long-Term Rescue of a Severe Spinal Muscular Atrophy Mouse Model","volume":"478","author":"Hua","year":"2011","journal-title":"Nature"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen Initiated in Infants during the Presymptomatic Stage of Spinal Muscular Atrophy: Interim Efficacy and Safety Results from the Phase 2 NURTURE Study","volume":"29","author":"Bertini","year":"2019","journal-title":"Neuromuscul. Disord."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mus.27853","article-title":"Continued Benefit of Nusinersen Initiated in the Presymptomatic Stage of Spinal Muscular Atrophy: 5-year Update of the NURTURE Study","volume":"68","author":"Crawford","year":"2023","journal-title":"Muscle Nerve"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-022-00612-2","article-title":"Amyotrophic Lateral Sclerosis: A Neurodegenerative Disorder Poised for Successful Therapeutic Translation","volume":"22","author":"Mead","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/B978-0-12-802973-2.00013-6","article-title":"The Epidemiology of Amyotrophic Lateral Sclerosis","volume":"Volume 138","author":"Talbott","year":"2016","journal-title":"Handbook of Clinical Neurology"},{"key":"ref_56","first-page":"61","article-title":"Riluzole: Real-World Evidence Supports Significant Extension of Median Survival Times in Patients with Amyotrophic Lateral Sclerosis","volume":"7","author":"Hinchcliffe","year":"2017","journal-title":"Degener. Neurol. Neuromuscul. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1111\/ene.14393","article-title":"Amyotrophic Lateral Sclerosis: A Clinical Review","volume":"27","author":"Masrori","year":"2020","journal-title":"Eur. J. Neurol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.3389\/fnins.2019.01310","article-title":"ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now?","volume":"13","author":"Mejzini","year":"2019","journal-title":"Front. Neurosci."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/nn.3584","article-title":"State of Play in Amyotrophic Lateral Sclerosis Genetics","volume":"17","author":"Renton","year":"2014","journal-title":"Nat. Neurosci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41588-021-00973-1","article-title":"Common and Rare Variant Association Analyses in Amyotrophic Lateral Sclerosis Identify 15 Risk Loci with Distinct Genetic Architectures and Neuron-Specific Biology","volume":"53","author":"Bakker","year":"2021","journal-title":"Nat. Genet."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nature20413","article-title":"Decoding ALS: From Genes to Mechanism","volume":"539","author":"Taylor","year":"2016","journal-title":"Nature"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/362059a0","article-title":"Mutations in Cu\/Zn Superoxide Dismutase Gene Are Associated with Familial Amyotrophic Lateral Sclerosis","volume":"362","author":"Rosen","year":"1993","journal-title":"Nature"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40035-016-0050-8","article-title":"Genotype-Phenotype Correlations of Amyotrophic Lateral Sclerosis","volume":"5","author":"Li","year":"2016","journal-title":"Transl. Neurodegener."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1146\/annurev.neuro.27.070203.144244","article-title":"Unraveling the Mechanisms Involved in Motor Neuron Degeneration in ALS","volume":"27","author":"Bruijn","year":"2004","journal-title":"Annu. Rev. Neurosci."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1365-2990.1996.tb00907.x","article-title":"Mechanisms of Selective Motor Neuron Death in ALS: Insights from Transgenic Mouse Models of Motor Neuron Disease","volume":"22","author":"Bruijn","year":"1996","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1038\/mt.2013.211","article-title":"Therapeutic AAV9-Mediated Suppression of Mutant SOD1 Slows Disease Progression and Extends Survival in Models of Inherited ALS","volume":"21","author":"Foust","year":"2013","journal-title":"Mol. Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nm1207","article-title":"Lentiviral-Mediated Silencing of SOD1 through RNA Interference Retards Disease Onset and Progression in a Mouse Model of ALS","volume":"11","author":"Raoul","year":"2005","journal-title":"Nat. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1474-4422(13)70061-9","article-title":"An Antisense Oligonucleotide against SOD1 Delivered Intrathecally for Patients with SOD1 Familial Amyotrophic Lateral Sclerosis: A Phase 1, Randomised, First-in-Man Study","volume":"12","author":"Miller","year":"2013","journal-title":"Lancet Neurol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1152\/jn.00398.2021","article-title":"Phosphorylated Neurofilament Heavy Chain: A Potential Diagnostic Biomarker in Amyotrophic Lateral Sclerosis","volume":"127","author":"Heckler","year":"2022","journal-title":"J. Neurophysiol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2003715","article-title":"Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS","volume":"383","author":"Miller","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","article-title":"Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS","volume":"387","author":"Miller","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"102495","DOI":"10.1016\/j.eclinm.2024.102495","article-title":"Effects of Tofersen Treatment in Patients with SOD1-ALS in a \u201cReal-World\u201d Setting\u2014A 12-Month Multicenter Cohort Study from the German Early Access Program","volume":"69","author":"Wiesenfarth","year":"2024","journal-title":"EClinicalMedicine"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1007\/s13311-022-01237-4","article-title":"Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: The ATLAS Study","volume":"19","author":"Benatar","year":"2022","journal-title":"Neurotherapeutics"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1474-4422(12)70043-1","article-title":"Frequency of the C9orf72 Hexanucleotide Repeat Expansion in Patients with Amyotrophic Lateral Sclerosis and Frontotemporal Dementia: A Cross-Sectional Study","volume":"11","author":"Majounie","year":"2012","journal-title":"Lancet Neurol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.neuron.2011.09.010","article-title":"A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD","volume":"72","author":"Renton","year":"2011","journal-title":"Neuron"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.neuron.2011.09.011","article-title":"Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS","volume":"72","author":"Mackenzie","year":"2011","journal-title":"Neuron"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nrn.2016.38","article-title":"The Expanding Biology of the C9orf72 Nucleotide Repeat Expansion in Neurodegenerative Disease","volume":"17","author":"Haeusler","year":"2016","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.celrep.2013.10.049","article-title":"Hexanucleotide Repeats in ALS\/FTD Form Length-Dependent RNA Foci, Sequester RNA Binding Proteins, and Are Neurotoxic","volume":"5","author":"Lee","year":"2013","journal-title":"Cell Rep."},{"key":"ref_79","first-page":"1787","article-title":"Nuclear Accumulation of mRNAs Underlies G4C2-Repeat-Induced Translational Repression in a Cellular Model of C9orf72 ALS","volume":"128","author":"Rossi","year":"2015","journal-title":"J. Cell Sci."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00401-014-1329-4","article-title":"C9orf72 FTLD\/ALS-Associated Gly-Ala Dipeptide Repeat Proteins Cause Neuronal Toxicity and Unc119 Sequestration","volume":"128","author":"May","year":"2014","journal-title":"Acta Neuropathol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00401-014-1336-5","article-title":"Aggregation-Prone c9FTD\/ALS Poly(GA) RAN-Translated Proteins Cause Neurotoxicity by Inducing ER Stress","volume":"128","author":"Zhang","year":"2014","journal-title":"Acta Neuropathol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/s41591-018-0071-1","article-title":"Poly(GR) Impairs Protein Translation and Stress Granule Dynamics in C9orf72-Associated Frontotemporal Dementia and Amyotrophic Lateral Sclerosis","volume":"24","author":"Zhang","year":"2018","journal-title":"Nat. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1126\/science.aaf1064","article-title":"C9orf72 Is Required for Proper Macrophage and Microglial Function in Mice","volume":"351","author":"Bogdanik","year":"2016","journal-title":"Science"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"347ra93","DOI":"10.1126\/scitranslmed.aaf6038","article-title":"Loss-of-Function Mutations in the C9ORF72 Mouse Ortholog Cause Fatal Autoimmune Disease","volume":"8","author":"Burberry","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.neuron.2013.10.015","article-title":"RNA Toxicity from the ALS\/FTD C9ORF72 Expansion Is Mitigated by Antisense Intervention","volume":"80","author":"Donnelly","year":"2013","journal-title":"Neuron"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.neuron.2016.04.006","article-title":"Gain of Toxicity from ALS\/FTD-Linked Repeat Expansions in C9ORF72 Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC-Containing RNAs","volume":"90","author":"Jiang","year":"2016","journal-title":"Neuron"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e1605","DOI":"10.1212\/WNL.0000000000008359","article-title":"Prospective Natural History Study of C9orf72 ALS Clinical Characteristics and Biomarkers","volume":"93","author":"Cammack","year":"2019","journal-title":"Neurology"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41591-021-01557-6","article-title":"Suppression of Mutant C9orf72 Expression by a Potent Mixed Backbone Antisense Oligonucleotide","volume":"28","author":"Tran","year":"2022","journal-title":"Nat. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s13311-022-01247-2","article-title":"Antisense Oligonucleotides for the Study and Treatment of ALS","volume":"19","author":"Boros","year":"2022","journal-title":"Neurotherapeutics"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/s41467-021-21112-8","article-title":"Variant-Selective Stereopure Oligonucleotides Protect against Pathologies Associated with C9orf72-Repeat Expansion in Preclinical Models","volume":"12","author":"Liu","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.omtn.2022.04.007","article-title":"Preclinical Evaluation of WVE-004, Aninvestigational Stereopure Oligonucleotide Forthe Treatment of C9orf72-Associated ALS or FTD","volume":"28","author":"Liu","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_92","first-page":"E4530","article-title":"Targeted Degradation of Sense and Antisense C9orf72 RNA Foci as Therapy for ALS and Frontotemporal Degeneration","volume":"110","author":"Baughn","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"208ra149","DOI":"10.1126\/scitranslmed.3007529","article-title":"Targeting RNA Foci in iPSC-Derived Motor Neurons from ALS Patients with a C9ORF72 Repeat Expansion","volume":"5","author":"Sareen","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/jnc.13625","article-title":"Physiological Functions and Pathobiology of TDP-43 and FUS\/TLS Proteins","volume":"138","author":"Ratti","year":"2016","journal-title":"J. Neurochem."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1093\/hmg\/ddt117","article-title":"ALS Mutant FUS Disrupts Nuclear Localization and Sequesters Wild-Type FUS within Cytoplasmic Stress Granules","volume":"22","author":"Vance","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00401-012-1043-z","article-title":"Overexpression of Human Wild-Type FUS Causes Progressive Motor Neuron Degeneration in an Age- and Dose-Dependent Fashion","volume":"125","author":"Mitchell","year":"2013","journal-title":"Acta Neuropathol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41591-021-01615-z","article-title":"Antisense Oligonucleotide Silencing of FUS Expression as a Therapeutic Approach in Amyotrophic Lateral Sclerosis","volume":"28","author":"Korobeynikov","year":"2022","journal-title":"Nat. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/nan.12148","article-title":"Loss of Nuclear TDP -43 in Amyotrophic Lateral Sclerosis ( ALS ) Causes Altered Expression of Splicing Machinery and Widespread Dysregulation of RNA Splicing in Motor Neurones","volume":"40","author":"Highley","year":"2014","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"800","DOI":"10.4103\/1673-5374.382233","article-title":"The Pathogenic Mechanism of TAR DNA-Binding Protein 43 (TDP-43) in Amyotrophic Lateral Sclerosis","volume":"19","author":"Wang","year":"2024","journal-title":"Neural Regen. Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1038\/nn.3230","article-title":"Divergent Roles of ALS-Linked Proteins FUS\/TLS and TDP-43 Intersect in Processing Long Pre-mRNAs","volume":"15","author":"Polymenidou","year":"2012","journal-title":"Nat. Neurosci."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nn.2779","article-title":"Long Pre-mRNA Depletion and RNA Missplicing Contribute to Neuronal Vulnerability from Loss of TDP-43","volume":"14","author":"Polymenidou","year":"2011","journal-title":"Nat. Neurosci."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.brainres.2012.04.031","article-title":"Rodent Models of TDP-43: Recent Advances","volume":"1462","author":"Tsao","year":"2012","journal-title":"Brain Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1172\/JCI44867","article-title":"Dysregulation of the ALS-Associated Gene TDP-43 Leads to Neuronal Death and Degeneration in Mice","volume":"121","author":"Igaz","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41593-018-0300-4","article-title":"ALS-Implicated Protein TDP-43 Sustains Levels of STMN2, a Mediator of Motor Neuron Growth and Repair","volume":"22","author":"Klim","year":"2019","journal-title":"Nat. Neurosci."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"111001","DOI":"10.1016\/j.celrep.2022.111001","article-title":"Loss of Stathmin-2, a Hallmark of TDP-43-Associated ALS, Causes Motor Neuropathy","volume":"39","author":"Krus","year":"2022","journal-title":"Cell Rep."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1126\/science.abq5622","article-title":"Mechanism of STMN2 Cryptic Splice-Polyadenylation and Its Correction for TDP-43 Proteinopathies","volume":"379","author":"Baughn","year":"2023","journal-title":"Science"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nature22044","article-title":"Antisense Oligonucleotide Therapy for Spinocerebellar Ataxia Type 2","volume":"544","author":"Scoles","year":"2017","journal-title":"Nature"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nature22038","article-title":"Therapeutic Reduction of Ataxin-2 Extends Lifespan and Reduces Pathology in TDP-43 Mice","volume":"544","author":"Becker","year":"2017","journal-title":"Nature"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1212\/WNL.0b013e31821f445b","article-title":"Expanded ATXN2 CAG Repeat Size in ALS Identifies Genetic Overlap between ALS and SCA2","volume":"76","author":"Veldink","year":"2011","journal-title":"Neurology"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1212\/WNL.18.7.671","article-title":"Progressive Proximal Spinal and Bulbar Muscular Atrophy of Late Onset: A Sex-linked Recessive Trait","volume":"18","author":"Kennedy","year":"1968","journal-title":"Neurology"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00441-012-1377-9","article-title":"Pathogenesis and Molecular Targeted Therapy of Spinal and Bulbar Muscular Atrophy (SBMA)","volume":"349","author":"Banno","year":"2012","journal-title":"Cell Tissue Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1023\/A:1014580219761","article-title":"Epidemiological Survey of X-Linked Bulbar and Spinal Muscular Atrophy, or Kennedy Disease, in the Province of Reggio Emilia, Italy","volume":"17","author":"Guidetti","year":"2001","journal-title":"Eur. J. Epidemiol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1093\/brain\/awp258","article-title":"Clinical Features of Spinal and Bulbar Muscular Atrophy","volume":"132","author":"Rhodes","year":"2009","journal-title":"Brain"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S1474-4422(10)70321-5","article-title":"Efficacy and Safety of Dutasteride in Patients with Spinal and Bulbar Muscular Atrophy: A Randomised Placebo-Controlled Trial","volume":"10","author":"Kokkinis","year":"2011","journal-title":"Lancet Neurol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/352077a0","article-title":"Androgen Receptor Gene Mutations in X-Linked Spinal and Bulbar Muscular Atrophy","volume":"352","author":"Wilson","year":"1991","journal-title":"Nature"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1399-0004.1996.tb02367.x","article-title":"Mitotic and Meiotic Stability of the CAG Repeat in the X-Linked Spinal and Bulbar Muscular Atrophy Gene","volume":"50","author":"Watanabe","year":"1996","journal-title":"Clin. Genet."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1172\/JCI80278","article-title":"Fighting Polyglutamine Disease by Wrestling with SUMO","volume":"125","author":"Craig","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/WCO.0000000000000856","article-title":"Molecular Pathogenesis of Spinal Bulbar Muscular Atrophy (Kennedy\u2019s Disease) and Avenues for Treatment","volume":"33","author":"Grunseich","year":"2020","journal-title":"Curr. Opin. Neurol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.celrep.2014.02.008","article-title":"Peripheral Androgen Receptor Gene Suppression Rescues Disease in Mouse Models of Spinal and Bulbar Muscular Atrophy","volume":"7","author":"Lieberman","year":"2014","journal-title":"Cell Rep."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"5985","DOI":"10.1093\/hmg\/ddv300","article-title":"Silencing Neuronal Mutant Androgen Receptor in a Mouse Model of Spinal and Bulbar Muscular Atrophy","volume":"24","author":"Sahashi","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2004929","DOI":"10.1002\/advs.202004929","article-title":"Delivering Antisense Oligonucleotides across the Blood-Brain Barrier by Tumor Cell-Derived Small Apoptotic Bodies","volume":"8","author":"Wang","year":"2021","journal-title":"Adv. Sci."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1021\/acsnano.2c09752","article-title":"An Antisense Oligonucleotide-Loaded Blood\u2013Brain Barrier Penetrable Nanoparticle Mediating Recruitment of Endogenous Neural Stem Cells for the Treatment of Parkinson\u2019s Disease","volume":"17","author":"Sun","year":"2023","journal-title":"ACS Nano"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1007\/s40120-023-00548-8","article-title":"Roadmap for C9ORF72 in Frontotemporal Dementia and Amyotrophic Lateral Sclerosis: Report on the C9ORF72 FTD\/ALS Summit","volume":"12","author":"Sattler","year":"2023","journal-title":"Neurol. Ther."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.molmed.2023.12.003","article-title":"The Sense of Antisense Therapies in ALS","volume":"30","author":"Masrori","year":"2024","journal-title":"Trends Mol. Med."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41593-020-0619-5","article-title":"Reduced C9ORF72 Function Exacerbates Gain of Toxicity from ALS\/FTD-Causing Repeat Expansion in C9orf72","volume":"23","author":"Zhu","year":"2020","journal-title":"Nat. Neurosci."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1146\/annurev-genom-111221-103208","article-title":"Diverse Molecular Mechanisms Underlying Pathogenic Protein Mutations: Beyond the Loss-of-Function Paradigm","volume":"23","author":"Backwell","year":"2022","journal-title":"Annu. Rev. Genom. Hum. Genet."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s43856-023-00419-1","article-title":"Possibilities and Limitations of Antisense Oligonucleotide Therapies for the Treatment of Monogenic Disorders","volume":"4","author":"Lauffer","year":"2024","journal-title":"Commun. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.omtn.2021.11.015","article-title":"Allele-Specific Targeting of Mutant Ataxin-3 by Antisense Oligonucleotides in SCA3-iPSC-Derived Neurons","volume":"27","author":"Hauser","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Skotte, N.H., Southwell, A.L., \u00d8stergaard, M.E., Carroll, J.B., Warby, S.C., Doty, C.N., Petoukhov, E., Vaid, K., Kordasiewicz, H., and Watt, A.T. (2014). Allele-Specific Suppression of Mutant Huntingtin Using Antisense Oligonucleotides: Providing a Therapeutic Option for All Huntington Disease Patients. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0107434"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1093\/brain\/awac063","article-title":"A Case of SOD1 Deficiency: Implications for Clinical Trials","volume":"145","author":"Farrimond","year":"2022","journal-title":"Brain"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.stem.2023.01.005","article-title":"SYF2 Suppression Mitigates Neurodegeneration in Models of Diverse Forms of ALS","volume":"30","author":"Linares","year":"2023","journal-title":"Cell Stem Cell"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40139-021-00227-z","article-title":"Toxicology of Nanoparticles in Drug Delivery","volume":"9","author":"Sharma","year":"2021","journal-title":"Curr. Pathobiol. Rep."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.nmd.2021.03.007","article-title":"Newborn Screening Programs for Spinal Muscular Atrophy Worldwide: Where We Stand and Where to Go","volume":"31","author":"Dangouloff","year":"2021","journal-title":"Neuromuscul. Disord."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/9\/4809\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:35:06Z","timestamp":1760106906000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/9\/4809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,28]]},"references-count":133,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["ijms25094809"],"URL":"https:\/\/doi.org\/10.3390\/ijms25094809","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,28]]}}}